

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "Version With Markings to Show Changes Made".

Respectfully submitted,

 (33,103) for

Anthony J. Zelano, Reg. No. 27,969

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1

2200 Clarendon Boulevard, Suite 1400

Arlington, VA 22201

Direct Dial: 703-812-5311

Facsimile: 703-243-6410

Email: zelano@mwzb.com

AJZ:jmm

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Claims 5-6, 11, and 13-19 have been amended as follows:

5. (Amended) Protein according to ~~one of the preceding claims 1~~, whereby protective groups are arranged at the N-terminus and/or the C-terminus.
6. (Amended) Protein according to ~~one of the preceding claims 1~~, which is a recombinant protein.
11. (Amended) Vector that contains a cDNA or DNA according to ~~one of claims 7 to 10~~, and a suitable promoter and optionally a suitable enhancer.
13. (Amended) Protein according to ~~one of claims 1 to 6~~ as a pharmaceutical active ingredient.
14. (Amended) Pharmaceutical composition that contains one of the proteins according to ~~one of claims 1 to 6~~ or a mixture thereof in the presence of pharmaceutically compatible and acceptable compounds and vehicles.
15. (Amended) Process for synthesizing one of the proteins according to ~~one of the preceding claims 1 to 6~~, whereby the proteins are synthesized according to the solid-phase method or according to the liquid-phase method.
16. (Amended) Binding molecules, single-chain proteins, antibodies or fragments of antibodies that specifically detect domains on the mature protein according to ~~one of the preceding claims 1 to 6~~.
17. (Amended) Use of one of the proteins according to ~~one of claims 1 to 6~~ or mixture thereof for the production of a medication for treating infections that were caused by microorganisms or for prevention of such infections.
18. (Amended) Bandage with at least one protein according to ~~one of the preceding claims 1 to 6~~ or with syngeneic or allogeneic human cells that are transfected with the DNA or cDNA according to one of claims 7 to 10.
19. (Amended) Use of at least one protein according to ~~one of the preceding claims 1 to 6~~ for the production of antibodies or fragments thereof.

*** RX REPORT ***

RECEPTION OK

TX/RX NO	6289	
CONNECTION TEL		7032436410
SUBADDRESS		
CONNECTION ID		
ST. TIME	03/27 16:36	
USAGE T	02'25	
PGS.	10	
RESULT	OK	